{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:00:26Z","timestamp":1792792826475,"version":"4.5.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104206"],"award-info":[{"award-number":["82104206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373890"],"award-info":[{"award-number":["82373890"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bcp.2025.116803","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T15:49:32Z","timestamp":1739720972000},"page":"116803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Parps in immune response: Potential targets for cancer immunotherapy"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-260X","authenticated-orcid":false,"given":"Shuping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116803_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the Immune System: The History and Background of Immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.bcp.2025.116803_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2025.116803_b0015","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of Immunotherapy Combination Strategies in Cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2025.116803_b0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","article-title":"Treatment of hairy cell leukemia with recombinant \u03b1-interferon","volume":"68","author":"Quesada","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.116803_b0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bjh.17440","article-title":"The current role of interferon in hairy cell leukaemia: clinical and molecular aspects","volume":"194","author":"Assanto","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2025.116803_b0030","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0035","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0040","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5825401","article-title":"Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy","volume":"2020","author":"Igarashi","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bcp.2025.116803_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2025.116803_b0050","first-page":"e550","article-title":"Immunotherapy for cancer treatment during pregnancy, Lancet","volume":"22","author":"Borgers","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.bcp.2025.116803_b0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bcp.2025.116803_b0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.116803_b0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036863","article-title":"New Approaches on Cancer Immunotherapy","volume":"10","author":"Cha","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0070","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.3390\/ijms22126532","article-title":"Ovarian Cancer Immunotherapy and Personalized Medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-022-06665-6","article-title":"Clinical trials of immunotherapy in triple-negative breast cancer","volume":"195","author":"Howard","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2025.116803_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.116803_b0090","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.trecan.2022.04.001","article-title":"Utilizing chemokines in cancer immunotherapy","volume":"8","author":"M\u00e4rkl","year":"2022","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity, CA","volume":"70","author":"Kennedy","year":"2020","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bcp.2025.116803_b0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance Mechanisms to Anti-PD Cancer Immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2025.116803_b0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tibs.2009.12.003","article-title":"Toward a unified nomenclature for mammalian ADP-ribosyltransferases","volume":"35","author":"Hottiger","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0115","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1038\/ncomms5426","article-title":"Family-wide analysis of poly(ADP-ribose) polymerase activity","volume":"5","author":"Vyas","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116803_b0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","article-title":"PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification","volume":"53","author":"Langelier","year":"2018","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0125","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.116803_b0130","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/pathogens12070964","article-title":"PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages","volume":"12","author":"Santinelli-Pestana","year":"2023","journal-title":"Pathog."},{"key":"10.1016\/j.bcp.2025.116803_b0135","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.molcel.2021.05.009","article-title":"XRCC1 prevents toxic PARP1 trapping during DNA base excision repair","volume":"81","author":"Demin","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.116803_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102651","article-title":"PARP-1 and its associated nucleases in DNA damage response","volume":"81","author":"Wang","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bcp.2025.116803_b0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/cancers12030739","article-title":"The Multifactorial Role of PARP-1 in Tumor Microenvironment","volume":"12","author":"Mart\u00ed","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.116803_b0150","first-page":"136","article-title":"PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3, Cancer","volume":"7","author":"Ding","year":"2019","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bcp.2025.116803_b0155","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1002\/cam4.4034","article-title":"PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer","volume":"10","author":"Ji","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2025.116803_b0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2021.09.024","article-title":"The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma","volume":"81","author":"Hagiwara","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2025.116803_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0170","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"Extending Benefit Beyond BRCA-Mutant Cancers","volume":"25","author":"Pili\u00e9","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116803_b0175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0185","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60637","article-title":"PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response","volume":"9","author":"Kim","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2025.116803_b0190","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.molcel.2022.03.034","article-title":"Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS","volume":"82","author":"Wang","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.116803_b0195","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1021\/acs.jmedchem.2c01452","article-title":"Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors","volume":"66","author":"Gu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116803_b0200","article-title":"Coronavirus infection and PARP expression dysregulate the NAD Metabolome: an actionable component of innate immunity","volume":"66","author":"Heer","year":"2020","journal-title":"BioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0205","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ccell.2021.06.018","article-title":"PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity","volume":"39","author":"Gozgit","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.116803_b0210","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2025.116803_b0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11010-019-03499-7","article-title":"SAMD9 is a (epi-) genetically regulated anti-inflammatory factor activated in RA patients","volume":"456","author":"He","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bcp.2025.116803_b0220","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/s41467-021-23003-4","article-title":"Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells","volume":"12","author":"Xing","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116803_b0225","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/eji.201646757","article-title":"Robust immunoglobulin class switch recombination and end joining in Parp9-deficient mice","volume":"47","author":"Robert","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0230","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/s41564-019-0582-7","article-title":"PARP11 regulates total levels of type-I interferon receptor IFNAR1","volume":"4","author":"Guo","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.bcp.2025.116803_b0235","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s43018-022-00383-0","article-title":"Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors","volume":"3","author":"Zhang","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0240","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3389\/fmicb.2020.01912","article-title":"Zinc Finger CCCH-Type Antiviral Protein 1 Restricts the Viral Replication by Positively Regulating Type I Interferon Response","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bcp.2025.116803_b0245","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1038\/ncomms6362","article-title":"PARP13 regulates cellular mRNA post-transcriptionally and functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript","volume":"5","author":"Todorova","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116803_b0250","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molmed.2015.03.002","article-title":"Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer","volume":"21","author":"Todorova","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0255","first-page":"1158","article-title":"A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants, Cell","volume":"28","author":"Schenkel","year":"2021","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0260","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.4049\/jimmunol.1701117","article-title":"PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN-Inducible Proteins","volume":"200","author":"Caprara","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0265","first-page":"1","article-title":"Introduction to the Immune System","volume":"2019","author":"McComb","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-1115-8_1","article-title":"A brief outline of the immune system","volume":"1184","author":"Tomar","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0275","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0280","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0285","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune Checkpoint Inhibitors: Basics and Challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116803_b0290","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0295","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","article-title":"IFN\u03b1 Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment","volume":"12","author":"Hu","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2025.116803_b0300","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0305","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/gutjnl-2022-327059","article-title":"Engineered anti-PDL1 with IFN\u03b1 targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance","volume":"72","author":"Meng","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2025.116803_b0310","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0315","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5409","article-title":"Interleukin-2-based therapies in cancer","volume":"14","author":"Raeber","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641307","article-title":"Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer","volume":"12","author":"Sutherland","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0325","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/978-1-4939-3387-7_43","article-title":"Cancer Vaccines: A Brief Overview","volume":"1403","author":"Thomas","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0330","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/bs.ai.2015.12.001","article-title":"Advances in Therapeutic Cancer Vaccines","volume":"130","author":"Wong","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2025.116803_b0340","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI123391","article-title":"Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity","volume":"129","author":"Pai","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.116803_b0345","doi-asserted-by":"crossref","first-page":"10902","DOI":"10.3390\/ijms231810902","article-title":"CTLA4-Linked Autoimmunity in the Pathogenesis of Endometriosis and Related Infertility: A Systematic Review","volume":"23","author":"Miku\u0161","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0350","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/EDBK_156572","article-title":"Basic Overview of Current Immunotherapy Approaches in Cancer","volume":"35","author":"Velcheti","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book. Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"10.1016\/j.bcp.2025.116803_b0355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1101\/cshperspect.a036863","article-title":"New Approaches on Cancer Immunotherapy","volume":"10","author":"Cha","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0360","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1093\/nar\/gkad514","article-title":"Updated protein domain annotation of the PARP protein family sheds new light on biological function","volume":"51","author":"Suskiewicz","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.116803_b0365","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bcp.2014.08.026","article-title":"PARP and other prospective targets for poisoning cancer cell metabolism","volume":"92","author":"Michels","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116803_b0370","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.molcel.2015.05.007","article-title":"Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation","volume":"58","author":"Barkauskaite","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.116803_b0375","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","article-title":"The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2025.116803_b0380","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.1216338","article-title":"Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1","volume":"336","author":"Langelier","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.116803_b0385","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tim.2021.01.002","article-title":"When PARPs Meet Antiviral Innate Immunity","volume":"29","author":"Zhu","year":"2021","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bcp.2025.116803_b0390","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1111\/febs.12388","article-title":"Pharmacology of ADP-ribosylation","volume":"280","author":"Sch\u00fcler","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2025.116803_b0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1134\/S1607672918050010","article-title":"A New DNA Break Repair Pathway Involving PARP3 and Base Excision Repair Proteins","volume":"482","author":"Belousova","year":"2018","journal-title":"Dokl. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2025.116803_b0400","first-page":"206","article-title":"Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics, Anticancer. Agents","volume":"19","author":"Li","year":"2019","journal-title":"Med. Chem."},{"key":"10.1016\/j.bcp.2025.116803_b0405","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1039\/C3MB70305C","article-title":"Molecular insights on TNKS1\/TNKS2 and inhibitor-IWR1 interactions","volume":"10","author":"Kirubakaran","year":"2014","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.bcp.2025.116803_b0410","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3892\/ol.2021.12949","article-title":"Dihydroartemisinin suppresses proliferation, migration, the Wnt\/\u03b2-catenin pathway and EMT via TNKS in gastric cancer","volume":"22","author":"Ma","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.116803_b0415","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/nar\/gkx083","article-title":"Tankyrase1-mediated poly(ADP-ribosyl)ation of TRF1 maintains cell survival after telomeric DNA damage","volume":"45","author":"Yang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.116803_b0420","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-022-05449-8","article-title":"Structural basis of tankyrase activation by polymerization","volume":"612","author":"Pillay","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.116803_b0425","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-017-02363-w","article-title":"Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation","volume":"8","author":"Bhardwaj","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116803_b0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009202","article-title":"Poly(ADP-ribose) potentiates ZAP antiviral activity","volume":"18","author":"Xue","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2025.116803_b0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2019.07.004","article-title":"Overview of the mammalian ADP-ribosyl-transferases clostridia toxin-like (ARTCs) family","volume":"167","author":"Di Girolamo","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116803_b0440","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2076310","article-title":"The ART of tumor immune escape","volume":"11","author":"Wennerberg","year":"2022","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.bcp.2025.116803_b0445","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe8195","article-title":"Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer","volume":"14","author":"Wennerberg","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0450","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jtho.2019.12.034","article-title":"A05 ART1, a Mono-ADP-Ribosyltransferase, Regulates Tumor-Infiltrating CD8+ T Cells and Is Highly Expressed in EGFR Mutated Lung Cancers","volume":"15","author":"Mukherjee","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2025.116803_b0455","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2025.116803_b0460","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0465","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0470","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.116803_b0475","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.116803_b0480","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1358\/dot.2019.55.7.3015642","article-title":"Talazoparib to treat BRCA-positive breast cancer","volume":"55","author":"Guney Eskiler","year":"2019","journal-title":"Drugs Today (barc)"},{"key":"10.1016\/j.bcp.2025.116803_b0485","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/13543784.2016.1146677","article-title":"Veliparib for the treatment of ovarian cancer","volume":"25","author":"Bogliolo","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2025.116803_b0490","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1535-7163.MCT-21-0841","article-title":"A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor","volume":"21","author":"Chen","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.116803_b0495","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00204-021-03134-9","article-title":"Aryl hydrocarbon receptor (AHR) functions in infectious and sterile inflammation and NAD+-dependent metabolic adaptation","volume":"95","author":"Bock","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2025.116803_b0500","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/ijms23020920","article-title":"Reduced Colonic Mucosal Injury in 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Poly ADP-Ribose Polymerase (TIPARP\/PARP7)-Deficient Mice","volume":"23","author":"Hutin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0505","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216235","article-title":"Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance","volume":"15","author":"Wang","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2025.116803_b0510","first-page":"1547","article-title":"A Potent and Selective PARP11 Inhibitor Suggests Coupling between Cellular Localization and Catalytic Activity, Cell","volume":"25","author":"Kirby","year":"2018","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0515","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/anie.201609655","article-title":"Small Molecule Microarray Based Discovery of PARP14 Inhibitors","volume":"56","author":"Peng","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2025.116803_b0520","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.116803_b0525","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2025.116803_b0530","doi-asserted-by":"crossref","first-page":"13356","DOI":"10.3390\/ijms232113356","article-title":"Interplay between the DNA Damage Response and Immunotherapy Response in Cancer","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0535","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-018-0629-6","article-title":"Nuclear cGAS suppresses DNA repair and promotes tumorigenesis","volume":"563","author":"Liu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.116803_b0540","first-page":"2983","article-title":"Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0545","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1093\/nar\/gkac188","article-title":"PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites","volume":"50","author":"Lin","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.116803_b0550","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11864-022-00938-4","article-title":"Appropriate Selection of PARP Inhibitors in Ovarian Cancer","volume":"23","author":"Smith","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.bcp.2025.116803_b0555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1264327","article-title":"Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors","volume":"14","author":"Roy","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0560","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00018-022-04138-z","article-title":"PARP-1 regulates inflammasome activity by poly-ADP-ribosylation of NLRP3 and interaction with TXNIP in primary macrophages","volume":"79","author":"Chiu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0565","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.762989","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102973","article-title":"PARP and PD-1\/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer","volume":"152","author":"Post","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bcp.2025.116803_b0575","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2025.116803_b0580","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-032713-120156","article-title":"Innate immune sensing and signaling of cytosolic nucleic acids","volume":"32","author":"Wu","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0585","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molcel.2015.01.018","article-title":"Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death","volume":"57","author":"Ichim","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.116803_b0590","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.molimm.2020.12.037","article-title":"DNA damage-triggered activation of cGAS-STING pathway induces apoptosis in human keratinocyte HaCaT cells","volume":"131","author":"Li","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0595","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","article-title":"Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway","volume":"53","author":"Zhang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2025.116803_b0600","first-page":"218","article-title":"Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors","volume":"12","author":"Dutta","year":"2023","journal-title":"Biology (Basel)."},{"key":"10.1016\/j.bcp.2025.116803_b0605","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/2326-6066.CIR-22-0896","article-title":"ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers","volume":"11","author":"Xiao","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bcp.2025.116803_b0610","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14728222.2018.1471137","article-title":"Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells","volume":"22","author":"Sasidharan Nair","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2025.116803_b0615","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.116803_b0620","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.116803_b0625","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1073797","article-title":"The potential of PARP inhibitors in targeted cancer therapy and immunotherapy","volume":"9","author":"Hunia","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bcp.2025.116803_b0630","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116803_b0635","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/pathogens12030457","article-title":"IFN-Induced PARPs-Sensors of Foreign Nucleic Acids","volume":"12","author":"Biaesch","year":"2023","journal-title":"Pathog"},{"key":"10.1016\/j.bcp.2025.116803_b0640","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.116803_b0645","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.116803_b0650","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1042\/BCJ20210378","article-title":"PARP7 mono-ADP-ribosylates the agonist conformation of the androgen receptor in the nucleus","volume":"478","author":"Kamata","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2025.116803_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102402","article-title":"Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time","volume":"77","author":"Brooks","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0660","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/pathogens12070964","article-title":"PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages","volume":"12","author":"Santinelli-Pestana","year":"2023","journal-title":"Pathog"},{"key":"10.1016\/j.bcp.2025.116803_b0665","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60481","article-title":"Identification of PARP-7 substrates reveals a role for MARylation in microtubule control in ovarian cancer cells","volume":"10","author":"Palavalli Parsons","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2025.116803_b0670","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60480","article-title":"Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets","volume":"10","author":"Rodriguez","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2025.116803_b0675","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1021\/acsmedchemlett.2c00416","article-title":"Recent Discovery of PARP7 Inhibitors as Anticancer Agents","volume":"13","author":"Kargbo","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.116803_b0680","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chembiol.2022.11.012","article-title":"Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-\u03b2 signaling","volume":"30","author":"Sanderson","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0685","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccell.2023.02.005","article-title":"Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment","volume":"41","author":"Klement","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.116803_b0690","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34334","article-title":"Serine is the major residue for ADP-ribosylation upon DNA damage","volume":"7","author":"Palazzo","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2025.116803_b0695","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cbin.11272","article-title":"Long noncoding RNA SNHG16 promotes the tumorigenicity of cervical cancer cells by recruiting transcriptional factor SPI1 to upregulate PARP9","volume":"44","author":"Tao","year":"2020","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bcp.2025.116803_b0700","first-page":"4073","article-title":"PARP9 is overexpressed in human breast cancer and promotes cancer cell migration","volume":"16","author":"Tang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.116803_b0705","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/liv.14577","article-title":"Transcriptome-wide association study for persistent hepatitis B virus infection and related hepatocellular carcinoma","volume":"40","author":"Han","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.bcp.2025.116803_b0710","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2025.116803_b0715","article-title":"Shaping Polarization of Tumor-Associated Macrophages In Cancer Immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0720","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/cns.13380","article-title":"Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target","volume":"26","author":"Xu","year":"2020","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bcp.2025.116803_b0725","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41564-019-0428-3","article-title":"ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase \u03b2-TrCP","volume":"4","author":"Guo","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.bcp.2025.116803_b0730","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.antiviral.2017.06.002","article-title":"Ubiquitin C-terminal hydrolase-L3 promotes interferon antiviral activity by stabilizing type I-interferon receptor","volume":"144","author":"Zhao","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2025.116803_b0735","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.3390\/ijms22115801","article-title":"Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review","volume":"22","author":"Oura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0740","article-title":"Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bcp.2025.116803_b0745","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.celrep.2015.12.045","article-title":"Identifying Family-Member-Specific Targets of Mono-ARTDs by Using a Chemical Genetics Approach","volume":"14","author":"Carter-O\u2019Connell","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.bcp.2025.116803_b0750","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12920-023-01546-3","article-title":"Association of ZC3HAV1 single nucleotide polymorphisms with the susceptibility of Vogt-Koyanagi-Harada Disease","volume":"16","author":"Wu","year":"2023","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.bcp.2025.116803_b0755","doi-asserted-by":"crossref","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","article-title":"Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. u. s. a."},{"key":"10.1016\/j.bcp.2025.116803_b0760","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7150\/ijbs.7.651","article-title":"Dual roles of immune cells and their factors in cancer development and progression","volume":"7","author":"Zamarron","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2025.116803_b0765","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2020.10.034","article-title":"HPV post-infection microenvironment and cervical cancer","volume":"497","author":"Yuan","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.116803_b0770","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.721975","article-title":"HBV-Specific CD8+ T-Cell Tolerance in the Liver","volume":"12","author":"Baudi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0775","doi-asserted-by":"crossref","first-page":"18482","DOI":"10.18632\/aging.203296","article-title":"ZC3HAV1 promotes the proliferation and metastasis via regulating KRAS in pancreatic cancer","volume":"13","author":"Huang","year":"2021","journal-title":"Aging (Albany. NY)."},{"key":"10.1016\/j.bcp.2025.116803_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105096","article-title":"PARP14 is a writer, reader, and eraser of mono-ADP-ribosylation","volume":"299","author":"Torretta","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116803_b0785","first-page":"167","article-title":"Function and regulation of the mono-ADP-ribosyltransferase ARTD10","volume":"384","author":"Kaufmann","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0790","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/s44318-024-00126-0","article-title":"PARP14 and PARP9\/DTX3L regulate interferon-induced ADP-ribosylation","volume":"43","author":"Kar","year":"2024","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2025.116803_b0795","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.4155\/fmc-2020-0166","article-title":"Recent developments in PARP14 research","volume":"12","author":"Tauber","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bcp.2025.116803_b0800","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fphar.2019.00172","article-title":"Research Progress on PARP14 as a Drug Target","volume":"10","author":"Qin","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116803_b0805","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2025.116803_b0810","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1038\/s41467-023-41737-1","article-title":"PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFN\u03b3-driven acquired resistance in preclinical cancer models","volume":"14","author":"Wong","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116803_b0815","first-page":"4753","article-title":"Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model","volume":"15","author":"Refaat","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.116803_b0820","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1021\/acschembio.8b00567","article-title":"Combining Chemical Genetics with Proximity-Dependent Labeling Reveals Cellular Targets of Poly(ADP-ribose) Polymerase 14 (PARP14)","volume":"13","author":"Carter-O\u2019Connell","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2025.116803_b0825","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2687","article-title":"PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities","volume":"9","author":"\u0110uki\u0107","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2025.116803_b0830","doi-asserted-by":"crossref","first-page":"18732","DOI":"10.1074\/jbc.M611283200","article-title":"Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription","volume":"282","author":"Goenka","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116803_b0835","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41467-018-04522-z","article-title":"On the role of STAT1 and STAT6 ADP-ribosylation in the regulation of macrophage activation","volume":"9","author":"Begitt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116803_b0840","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.1038\/ncomms12849","article-title":"PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation","volume":"7","author":"Iwata","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116803_b0845","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4049\/jimmunol.1301106","article-title":"B cell-intrinsic and -extrinsic regulation of antibody responses by PARP14, an intracellular (ADP-ribosyl)transferase","volume":"191","author":"Cho","year":"2013","journal-title":"J. Immunol."},{"issue":"521\u2013531","key":"10.1016\/j.bcp.2025.116803_b0850","first-page":"e1","article-title":"Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease","volume":"131","author":"Mehrotra","year":"2013","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T20:22:16Z","timestamp":1745266936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":170,"alternative-id":["S0006295225000656"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116803","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parps in immune response: Potential targets for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116803"}}